Veteran leadership at the top. Accelerated development throughout.
[image placeholder – do not delete]
We are a global company committed to improving patient outcomes through the accelerated development and launch of important new treatment options for significant health conditions.
While the Sumitovant portfolio companies each focus on particular areas of human health, they share an unparalleled technology-enabled approach to drug discovery, development and commercialization that aims to accelerate and de-risk every aspect of the process from bench to bedside.
About Sumitovant Biopharma
Sumitovant Biopharma Ltd. (“Sumitovant”) is a global company whose single aim is to make a difference in the lives of people globally by harnessing the power of technology to develop innovative medicines faster and better. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon and operates out of offices in New York and London. Sumitovant is the parent company of five biopharma companies: Urovant, Enzyvant, Altavant and Spirovant and is the majority owner of Myovant, a publicly listed life sciences company.
Sumitovant is led by industry veteran, Myrtle Potter. As CEO, Potter has built a proven, leadership team that brings expertise and oversight to its family of five subsidiary biotech companies known as Vants. Sumitovant is the primary source of funding for each of the five Vants and also provides expert advice across a number of business and scientific disciplines to help the Vants accelerate the pace of medical innovation for patients who need new treatment options today. Sumitovant’s aim is to foster speed, agility, and efficiency as a core part of our biotech business model across the family of Vants as they advance their healthcare agendas around the global.
Sumitovant companies benefit from an unparalleled technology-enabled approach to drug discovery, development and commercialization that aims to accelerate and de-risk every aspect of the process from bench to bedside. This innovative model has fueled the company’s robust pipeline across its portfolio of companies with late stage clinical assets that are now moving to commercial stage. These treatments span a range of therapeutic areas with unmet medical needs including women’s and men’s health, urological diseases, rare diseases, and gene therapy.
Sumitovant’s potential competitive advantage is also powered by a robust technology platform comprising a computational ecosystem (DrugOME) and an embedded custom technology capability (Digital Innovation) that together help enable rapid and tailored data-driven decision-making across every aspect of the business.
Sumitovant’s proven leadership team, technology backbone and the support of industry powerhouse DSP, uniquely position Sumitovant and the Vants to accelerate the launch of important new treatment options and improve lives globally.
*Sumitovant is the majority shareholder of Myovant